• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

    9/24/24 8:00:00 AM ET
    $ALGS
    $HAE
    $NVO
    $PLRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $ALGS alert in real time by email

    SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company's global clinical development efforts and serve as a member of Aligos' Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases.

    "I am excited to welcome Hardean to Aligos as our Chief Medical Officer, with expertise across liver indications, including both MASH and CHB," said Lawrence Blatt, Ph.D., MBA, Chairman, President, and Chief Executive Officer of Aligos Therapeutics. "Following our recent positive topline data for ALG-055009 in MASH subjects, we look forward to his strategic vision as we progress towards later stage clinical development with our best-in-class pipeline of liver and viral therapies."

    "Joining Aligos at this time is a compelling opportunity, especially after the positive Phase 2a HERALD topline data readout," stated Hardean Achneck, MD, Chief Medical Officer at Aligos. "I look forward to partnering with the team to strategically lead the Company's current and future clinical development with the mission to improve patient outcomes."

    Most recently, Dr. Achneck served as the Senior Vice President and Head of Clinical Development at Pliant Therapeutics (NASDAQ:PLRX) where he oversaw all clinical programs, including those in hepatic diseases. Before joining Pliant, Dr. Achneck was the Vice President of Clinical Development and Clinical Research at Dicerna Therapeutics (NASDAQ:DRNA). Following its acquisition by Novo Nordisk (NYSE:NVO, NASDAQ:NOVO) in 2021, he continued his role at the Novo Nordisk Dicerna Transformational Research Unit. He successfully advanced liver-targeted oligonucleotide assets from early to late-stage development, notably xalnesiran for chronic hepatitis B. Prior to his tenure at Dicerna, Dr. Achneck led Medical Affairs and Clinical Development at Haemonetics Corporation (NYSE:HAE). Before this, he served as Vice President and Chief Medical Officer at Hemostemix Inc.

    Prior to his industry roles, Dr. Achneck was an Assistant Professor of Surgery and in Pathology at Duke University School of Medicine, with a co-appointment as Assistant Professor of Cardiovascular & Metabolic Disorders at Duke-National University of Singapore. Dr. Achneck holds an M.D. from Yale University School of Medicine and a B.A. in Molecular Biophysics & Biochemistry, magna cum laude, from Yale University. Licensed to practice medicine in the U.S. and EU, he has authored over 30 peer-reviewed publications and was named an inventor on several patents.

    About Aligos

    Aligos Therapeutics, Inc. (NASDAQ:ALGS) is a clinical stage biopharmaceutical company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) and viruses with high unmet medical need such as hepatitis B and coronaviruses.

    For more information, please visit www.aligos.com or follow us on LinkedIn or X.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered "forward-looking statements," including without limitation, statements regarding Aligos' financial results and performance as well as research and development activities, including regulatory status and the timing of announcements and updates relating to our regulatory filings and clinical trials. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos' clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, and other matters that could affect the sufficiency of Aligos' capital resources to fund operations. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos' Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2024 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.  

            

    Aligos Therapeutics

    Contact

    Jordyn Tarazi

    Vice President, Investor Relations & Corporate Communications

    +1 (650) 910-0427

    [email protected]

    Media Contact

    Inizio Evoke

    Jake Robison

    Vice President

    [email protected]



    Primary Logo

    Get the next $ALGS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALGS
    $HAE
    $NVO
    $PLRX

    CompanyDatePrice TargetRatingAnalyst
    Novo Nordisk A/S
    $NVO
    4/17/2025$64.00Outperform → Market Perform
    BMO Capital Markets
    Novo Nordisk A/S
    $NVO
    3/13/2025Hold → Buy
    Kepler
    Pliant Therapeutics Inc.
    $PLRX
    3/4/2025Buy → Hold
    Needham
    Pliant Therapeutics Inc.
    $PLRX
    3/4/2025Neutral
    Cantor Fitzgerald
    Pliant Therapeutics Inc.
    $PLRX
    3/3/2025Buy → Hold
    Stifel
    Pliant Therapeutics Inc.
    $PLRX
    3/3/2025Outperform → Market Perform
    Leerink Partners
    Novo Nordisk A/S
    $NVO
    3/3/2025Buy → Hold
    Stifel
    Novo Nordisk A/S
    $NVO
    2/12/2025Equal-Weight
    Morgan Stanley
    More analyst ratings

    $ALGS
    $HAE
    $NVO
    $PLRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, Chief Financial Officer Darecca James covered exercise/tax liability with 654 shares, decreasing direct ownership by 4% to 16,692 units (SEC Form 4)

      4 - HAEMONETICS CORP (0000313143) (Issuer)

      5/5/25 4:16:09 PM ET
      $HAE
      Medical/Dental Instruments
      Health Care
    • SEC Form 3 filed by new insider Chan Frank

      3 - HAEMONETICS CORP (0000313143) (Issuer)

      4/9/25 4:14:53 PM ET
      $HAE
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by President and CEO Blatt Lawrence

      4 - Aligos Therapeutics, Inc. (0001799448) (Issuer)

      3/4/25 4:33:51 PM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALGS
    $HAE
    $NVO
    $PLRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Novo Nordisk A/S downgraded by BMO Capital Markets with a new price target

      BMO Capital Markets downgraded Novo Nordisk A/S from Outperform to Market Perform and set a new price target of $64.00

      4/17/25 8:30:12 AM ET
      $NVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Novo Nordisk A/S upgraded by Kepler

      Kepler upgraded Novo Nordisk A/S from Hold to Buy

      3/13/25 8:17:45 AM ET
      $NVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pliant Therapeutics downgraded by Needham

      Needham downgraded Pliant Therapeutics from Buy to Hold

      3/4/25 8:19:24 AM ET
      $PLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALGS
    $HAE
    $NVO
    $PLRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Pliant Therapeutics Inc.

      SC 13G - PLIANT THERAPEUTICS, INC. (0001746473) (Subject)

      11/14/24 9:00:58 PM ET
      $PLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Aligos Therapeutics Inc.

      SC 13G/A - Aligos Therapeutics, Inc. (0001799448) (Subject)

      11/14/24 6:57:50 PM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Aligos Therapeutics Inc.

      SC 13G/A - Aligos Therapeutics, Inc. (0001799448) (Subject)

      11/14/24 6:19:11 PM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALGS
    $HAE
    $NVO
    $PLRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $ALGS
    $HAE
    $NVO
    $PLRX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

      Activities supporting the close out of BEACON-IPF continue; topline data expected in the second quarter of 2025 Recently announced strategic realignment of workforce and operations will extend cash runway to support execution of late-stage clinical trials SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a corporate update and reported first quarter 2025 financial results. "During the first quarter and over recent weeks, our teams have been working diligently to close out the g

      5/8/25 4:05:00 PM ET
      $PLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aligos Therapeutics Presents Positive Data at the EASL Congress 2025

      SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive data from eight presentations at the European Association for the Study of the Liver (EASL) Congress 2025, being held May 7 – 10, 2025 in Amsterdam, Netherlands. "We are pleased to have eight presentations at this year's EASL Congress from programs across our pipeline," stated Lawrence Blatt, PhD, MBA, Chairman, President, & CEO of Aligos Therapeutics. "In particular, we are excited to share an update on the 96-week data f

      5/8/25 8:00:00 AM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Haemonetics 4th Quarter and Fiscal Year 2025 Earnings Release Available on Investor Relations Website

      Financial release accessible online BOSTON, May 8, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its fourth quarter and fiscal year 2025, which ended March 29, 2025, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on May 8, 2025. The conference call and webcast can be accessed with the following information: Teleconference link:https://register-conf.media-server.com/register/BI8b22e12b2

      5/8/25 6:00:00 AM ET
      $HAE
      Medical/Dental Instruments
      Health Care
    • March 8, 2024 - FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight

      For Immediate Release: March 08, 2024 Today, the U.S. Food and Drug Administration approved a new indication for use for Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight. Wegovy should be used in addition to a reduced calorie diet and increased physical activity. Cardiovascular disease is a gr

      3/8/24 2:00:18 PM ET
      $NVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALGS
    $HAE
    $NVO
    $PLRX
    SEC Filings

    See more
    • SEC Form 6-K filed by Novo Nordisk A/S

      6-K - NOVO NORDISK A S (0000353278) (Filer)

      5/9/25 8:12:45 AM ET
      $NVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Pliant Therapeutics Inc.

      10-Q - PLIANT THERAPEUTICS, INC. (0001746473) (Filer)

      5/8/25 4:16:45 PM ET
      $PLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pliant Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - PLIANT THERAPEUTICS, INC. (0001746473) (Filer)

      5/8/25 4:11:00 PM ET
      $PLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALGS
    $HAE
    $NVO
    $PLRX
    Financials

    Live finance-specific insights

    See more
    • Haemonetics 4th Quarter and Fiscal Year 2025 Earnings Release Available on Investor Relations Website

      Financial release accessible online BOSTON, May 8, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its fourth quarter and fiscal year 2025, which ended March 29, 2025, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on May 8, 2025. The conference call and webcast can be accessed with the following information: Teleconference link:https://register-conf.media-server.com/register/BI8b22e12b2

      5/8/25 6:00:00 AM ET
      $HAE
      Medical/Dental Instruments
      Health Care
    • Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2025 Results: May 8, 2025

      BOSTON, March 31, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish fourth quarter and fiscal year 2025 financial results at 6:00 am ET on Thursday, May 8, 2025. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on May 8, 2025. The call can be accessed via teleconference at: Q4 2025 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call.

      3/31/25 4:00:00 PM ET
      $HAE
      Medical/Dental Instruments
      Health Care
    • Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement

      SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced that its Board of Directors has unanimously adopted a limited duration stockholder rights agreement (the "Rights Agreement") to protect stockholder interests. The Board resolved to adopt the Rights Agreement in response to recent accumulations of the Company's common stock. The Rights Agreement is intended to reduce the likelihood that any entity, person or group is able to gain control of Pliant through open market accumulation without paying all stockholders an appropriate control premium or providing the Board sufficient opportunity to make informed judgments and take

      3/13/25 7:20:00 AM ET
      $PLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALGS
    $HAE
    $NVO
    $PLRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results

      Discontinuation of BEACON-IPF following DSMB and outside expert panel recommendation SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a corporate update and reported fourth quarter 2024 financial results. Fourth Quarter and Recent Highlights Bexotegrast Highlights BEACON-IPF discontinued following recommendation from expanded data safety monitoring board (DSMB). Following a prespecified data review and recommendation by the trial's independent DSMB, as well as a secondary r

      3/3/25 4:05:00 PM ET
      $PLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pliant Therapeutics Appoints Delphine Imbert, Ph.D. as Chief Technical Officer

      Dr. Imbert brings 25 years of strategic clinical to commercial-stage manufacturing and drug development experience SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the appointment of Delphine Imbert, Ph.D. as Chief Technical Officer. Dr. Imbert brings 25 years of product development, process optimization and manufacturing experience across multiple drug modalities, including small molecules. In this role, Dr. Imbert will lead chemistry, manufacturing and control (CMC)-related acti

      1/22/25 8:00:00 AM ET
      $PLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

      BEACON-IPF Phase 2b trial on track for full enrollment in the first quarter of 2025 with data anticipated in mid-2026 SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a late-stage clinical biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a corporate update and reported third quarter 2024 financial results. "A highlight to this quarter's progress was the continued strong execution of our BEACON-IPF Phase 2b/3 trial which is enrolling well and on track to complete enrollment in the first quarter of 2025," said Bernard Coulie, M.D., Ph.D.

      11/7/24 4:05:00 PM ET
      $PLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care